Abstract：
BACKGROUND: According to the National Comprehensive Cancer Network Guidelines, 18F-fluciclovine PET/CT is considered appropriate after negative standard of care (SOC) imaging.
OBJECTIVE: To prospectively compare 18F-fluciclovine to SOC imaging, investigate whether it should be done when SOC imaging is (+), and evaluate its detection rate in patients receiving androgen deprivation therapy.
METHODS: We recruited 57 prostate cancer patients with biochemical recurrence with 18F-fluciclovine PET/CT and SOC imaging within 30 days. Prostate-specific antigen (PSA) level, Gleason score (GS), history of radical prostatectomy (RP), radiation therapy (RT) or hormone therapy (HT) were reviewed.
RESULTS: The 57 patients had a median PSA of 2.6 and average GS of 7.4; 27 (47.4%) had RP, 28 (49.1%) had RT, 1 (1.75%) had HT and 1 (1.75%) observation only. 18F-fluciclovine identified disease recurrence in 45/57 patients (78.9%), including oligometastasis in 18/45 (40%). SOC imaging identified recurrent disease in 12/57 patients (21.1%) while 18F-fluciclvoine identified additional sites of disease in 11/12 (91.7%). The (+) 18F-fluciclovine studies had a median PSA 2.6 ng/ml compared to 6.0 ng/ml in the (+) SOC studies.
CONCLUSIONS: 18F-fluciclovine was superior to SOC imaging for lesion detection, identification of oligometastasis and identification of additional sites of disease.
OBJECTIVE: To prospectively compare 18F-fluciclovine to SOC imaging, investigate whether it should be done when SOC imaging is (+), and evaluate its detection rate in patients receiving androgen deprivation therapy.
METHODS: We recruited 57 prostate cancer patients with biochemical recurrence with 18F-fluciclovine PET/CT and SOC imaging within 30 days. Prostate-specific antigen (PSA) level, Gleason score (GS), history of radical prostatectomy (RP), radiation therapy (RT) or hormone therapy (HT) were reviewed.
RESULTS: The 57 patients had a median PSA of 2.6 and average GS of 7.4; 27 (47.4%) had RP, 28 (49.1%) had RT, 1 (1.75%) had HT and 1 (1.75%) observation only. 18F-fluciclovine identified disease recurrence in 45/57 patients (78.9%), including oligometastasis in 18/45 (40%). SOC imaging identified recurrent disease in 12/57 patients (21.1%) while 18F-fluciclvoine identified additional sites of disease in 11/12 (91.7%). The (+) 18F-fluciclovine studies had a median PSA 2.6 ng/ml compared to 6.0 ng/ml in the (+) SOC studies.
CONCLUSIONS: 18F-fluciclovine was superior to SOC imaging for lesion detection, identification of oligometastasis and identification of additional sites of disease.
摘要：
背景：根据国家综合癌症网络指南，在负标准护理（SOC）成像后，认为18F-氟克柳树PET/CT是合适的。
目的：前瞻性比较18F-fluciclovine与SOC成像，调查是否应该在SOC成像为(+)时进行，并评估其在接受雄激素剥夺治疗的患者中的检出率。
方法：我们招募了57例生化复发的前列腺癌患者，在30天内进行了18F-fluciclovinePET/CT和SOC成像。前列腺特异性抗原(PSA)水平,格里森评分（GS），前列腺癌根治术（RP）的历史，对放射治疗（RT）或激素治疗（HT）进行了综述。
结果：57例患者的PSA中位数为2.6，平均GS为7.4；27例（47.4％）患有RP，28人（49.1%）有RT，1（1.75％）有HT和1（1.75％）仅观察。18F-fluciclovine在45/57患者中发现疾病复发（78.9％），包括18/45（40％）的寡转移。SOC成像在12/57患者中确定了复发性疾病（21.1％），而18F-氟西霉素在11/12中确定了其他疾病部位（91.7％）。与(+)SOC研究中的6.0ng/ml相比,(+)18F-氟克乳研究的中值PSA为2.6ng/ml。
结论：18F-fluciclovine在病变检测方面优于SOC成像，寡转移的鉴定和其他疾病部位的鉴定。
目的：前瞻性比较18F-fluciclovine与SOC成像，调查是否应该在SOC成像为(+)时进行，并评估其在接受雄激素剥夺治疗的患者中的检出率。
方法：我们招募了57例生化复发的前列腺癌患者，在30天内进行了18F-fluciclovinePET/CT和SOC成像。前列腺特异性抗原(PSA)水平,格里森评分（GS），前列腺癌根治术（RP）的历史，对放射治疗（RT）或激素治疗（HT）进行了综述。
结果：57例患者的PSA中位数为2.6，平均GS为7.4；27例（47.4％）患有RP，28人（49.1%）有RT，1（1.75％）有HT和1（1.75％）仅观察。18F-fluciclovine在45/57患者中发现疾病复发（78.9％），包括18/45（40％）的寡转移。SOC成像在12/57患者中确定了复发性疾病（21.1％），而18F-氟西霉素在11/12中确定了其他疾病部位（91.7％）。与(+)SOC研究中的6.0ng/ml相比,(+)18F-氟克乳研究的中值PSA为2.6ng/ml。
结论：18F-fluciclovine在病变检测方面优于SOC成像，寡转移的鉴定和其他疾病部位的鉴定。
